Jazz Pharmaceuticals Posts Record $1.2B Quarter, Raises 2026 Outlook
Jazz Pharmaceuticals reported record quarterly revenues of $1.2 billion, up 10% year-over-year, and lifted its full-year 2026 revenue guidance.
Jazz Pharmaceuticals delivered its strongest quarterly revenue performance on record in the third quarter of 2026, generating $1.2 billion in sales — a 10% increase compared with the same period a year earlier — as the company also moved to raise its full-year revenue guidance, signaling confidence in sustained commercial momentum.
Xywav, the company's oxybate therapy, was a key contributor to growth, with revenues climbing 12% year-over-year. The drug added 425 net patients during the quarter, reflecting continued uptake among its target patient population and reinforcing Xywav's position as a core revenue driver within Jazz's portfolio.
Read more ONE Gas Raises 2026 Guidance After Third Quarter Results →
The company also advanced its oncology pipeline, launching Ziihera in the first-line treatment setting for HER2-positive metastatic gastroesophageal adenocarcinoma. The launch represents a significant commercial expansion for Jazz in solid tumor oncology, a therapeutic area the company has been building out alongside its established sleep medicine franchise.
Jazz further broadened its portfolio during the quarter by closing its acquisition of Actio, a deal that adds pipeline assets and potential future revenue streams. The move underscores management's strategy of supplementing organic growth with targeted bolt-on acquisitions to diversify and strengthen long-term earnings capacity.
The combination of record top-line results, a guidance increase, a new product launch, and a completed acquisition positions Jazz heading into the fourth quarter of 2026 with multiple catalysts in play. Continue reading at Earnings.
